Newsletter sign up



Copyright 2018
Terms & Conditions


About Peter Hofland
About Peter Hofland Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved drug. He is also a contributor to Onco'Zine and The Onco'Zine Brief.

Articles by Peter


First Patients Enrolled in Landmark Lung Cancer Tri-Therapy Clinical Trial

Published on 19th January

As part of an international collaboration that looks to transform care for lung cancer patients the first patients have been enroll in a new cancer study at Avera, an integrated health system comprised of more than 330 locations in 100 communities in a five-state region offering a full continuum of care is offered through 32 hospitals, 200+ clinics, retirement communities, home care, sports and fitness centers

This clinical trial that received the approval of the U.S. Food and Drug Administration(FDA) is Avera’s latest collaboration as part its membership in the Worldwide Innovative Networking(WIN) Consortium.


If successful, this study could lead to a complete paradigm shift in our approach to lung cancer treatment with a goal of realizing big improvements in outcomes for patients…


“We’re taking a bold step in a new direction so lung cancer patients have hope for more treatment options after diagnosis. This latest step in our collaboration with WIN represents one clinical trial but is part of our larger goal to revolutionize cancer care through personalized medicine,” noted Benjamin Solomon, MD., the lead investigator for the study at Avera and medical oncologist with Avera Cancer Institute.

“If successful, this study could lead to a complete paradigm shift in our approach to lung cancer treatment with a goal of realizing big improvements in outcomes for patients,” he added.

More than 60% of non-small cell lung cancer cases are detected in an advanced stage, and less than 5% of these patients are alive five years after diagnosis.

In the Survival Prolongation by Rationale Innovative Genomics (SPRING) trial, patients will be given a three-drug protocol that incorporates the immunotherapeutic agent avelumab (Bavencio®; EMD Serono/Pfizer), a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody, and two other targeted therapies, palbociclib (Ibrance®;Pfizer) and  axitinib (Inlyta®;Pfizer) All patients will be given the same drug combination and their response rates will be tracked to see which patients respond best.

Through the WIN Consortium, an Avera research team under Solomon’s leadership has helped design and implement the clinical trial from the ground up.

Photo 1.0: Benjamin Solomon, MD, Avera Cancer Institute

“This breakthrough research is happening in Sioux Falls, S.D., because of the high level of expertise and commitment available here,” observed Vladimir Lazar, MD, PhD, founder and Chief Scientific and Operating Officer of the WIN Consortium.

“With these clinical trials we want to go beyond what is now possible so patients around the world can have more hope when they get a lung cancer diagnosis,” Lazar added.

Because cancer evolves as it grows, it can acquire more genomic complexity over time. DNA sequencing and RNA expression levels in tumor and normal tissues will help guide care by analyzing the patient’s cancer genomic abnormalities to determine the specific changes that have occurred. A multi-drug combination has the potential to treat lung cancer by blocking multiple cancer pathways that develop as a result of these genomic changes.

For the most effective results, researchers work to pair the drug combinations that may work best to combat each lung cancer genomic abnormality. To accomplish this, WIN developed an algorithm, SIMS (Simplified Interventional Mapping System), which is hypothesized to better predict personalized treatment for cancer patients.

The end goal is to pair every lung cancer genomic abnormality with an effective drug combination. This may lead to dozens of clinical trials aimed at accomplishing this goal. In the future, this treatment algorithm could potentially be expanded to other tumor types such as colon or breast cancer.

The SPRING trial will be led by Razelle Kurzrock, MD, at the University of California San Diego, Moores Cancer Center and co-led by Enriqueta Felip, MD, at the Vall d’Hebron Institute of Oncology in Barcelona, Spain. The trial is expected to be launched in five countries and eight WIN member sites. Avera, one of two sites in the U.S., is the first to begin enrolling patients.

The SPRING trial will be conducted in two phases. Phase I will explore the safety of the drug combination and determine the optimal doses for Phase II, which will explore the efficacy of this tri-therapy regimen in first-line treatment of metastatic non-small cell lung cancer.

The trial will have strict eligibility criteria and limited enrollment.


Last Editorial Review: January 19, 2018

Featured Image: Doctor examining a lung radiography. Courtesy: © 2010 – 2017 Fotolia. Used with permission. Photo 1.0: Benjamin Solomon, MD, Avera Cancer Institute. Used with permission.

Copyright © 2010 – 2018 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.


Print Friendly, PDF & Email

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are granting: Sunvalley Communication, 4960 S. Gilbert Road, Chandler, AZ, 85249, permission to email you. You may unsubscribe via the link found at the bottom of every email. (See our Email Privacy Policy (http://constantcontact.com/legal/privacy-statement) for details.) Emails are serviced by Constant Contact.